Combined Holdings of Fate Therapeutics (FATE) - Updated Daily
Gene TherapyGenomicsCAR-NK Gene TherapyStem CellsCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $531.52m |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 216 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$46.82 - ARKG$78.47 - ARKK | 0% |
| Description | |
|---|---|
| Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA. | |
| Website | |
| www.fatetherapeutics.com |
Research Notes and Commentary for FATE
January 29, 2021
Ark Trades and Storylines
Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...April 12, 2020